

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
May 14, 2015**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Novartis AG

File No. 1-15024 - CF#32006

Novartis AG submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 20-F filed on January 27, 2015.

Based on representations by Novartis AG that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

| | |
|-------------|--------------------------|
| Exhibit 4.2 | through January 27, 2025 |
| Exhibit 4.3 | through January 27, 2025 |
| Exhibit 4.4 | through January 27, 2025 |
| Exhibit 4.5 | through January 27, 2025 |
| Exhibit 4.6 | through January 27, 2025 |
| Exhibit 4.7 | through January 27, 2025 |

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary